AMAM

Ambrx Biopharma, Inc. Common Stock
AMAM

Overview Fund Activity
Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

42 hedge funds and large institutions have $789M invested in Ambrx Biopharma, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.

Holders
42
Holders Change
+12
Holders Change %
+40%
% of All Funds
0.66%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
18
Increased
13
Reduced
8
Closed
6
Calls
$4.87M
Puts
$3.92M
Net Calls
+$949K
Net Calls Change
-$9.86M

Top Buyers

1
DGM
1
Darwin Global Management
Jersey
$275M
2
FCM
2
Farallon Capital Management
California
$37.3M
3
PBA
3
Paradigm Biocapital Advisors
New York
$27.2M
4
CAM
4
Cormorant Asset Management
Massachusetts
$158M
5
Holocene Advisors
5
Holocene Advisors
New York
$15M

Top Sellers

1
CC
1
Commodore Capital
New York
$52.3M
2
VA
2
VR Adviser
New York
$40.9M
3
FI
3
Fosun International
China
$0
4
Simplex Trading
4
Simplex Trading
Illinois
$109K
5
Nomura Holdings
5
Nomura Holdings
Japan
$0
Name Market Value Shares Shares
Change 		Shares
Change %
TCIM
51
TOMS Capital Investment Management
New York
– – – –
1 2
3